MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company Operating Income 2011-2026 | LCI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 M | -237 M | 19.6 M | -262 M | 130 M | 86.4 M | 131 M | 226 M | 88.1 M | 18.8 M | 6.91 M | -1.18 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | -262 M | 2.47 M |
Quarterly Operating Income Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.7 M | -14.8 M | -13 M | -27.8 M | -22.1 M | -68.1 M | -8.15 M | -76.2 M | 2.85 M | -217 M | -15 K | -217 M | -15 K | 16.8 M | 9.4 M | 16.8 M | 9.4 M | 36.7 M | -342 M | 36.7 M | -342 M | 47.1 M | 40.7 M | 47.1 M | 40.7 M | 34.3 M | -20.3 M | 34.3 M | -20.3 M | 30.3 M | 51.4 M | 30.3 M | 51.4 M | 66.5 M | 54.7 M | 66.5 M | 54.7 M | 25.4 M | -10.6 M | 25.4 M | -10.6 M | 4.69 M | 3.69 M | 4.69 M | 3.69 M | 495 K | 1.44 M | 495 K | 1.45 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.5 M | -342 M | -13.2 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.28 | 2.15 % | $ 60.2 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.4 | 0.42 % | $ 316 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.67 | 1.61 % | $ 2.07 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.15 | -4.17 % | $ 124 M | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 40.48 | -2.25 % | $ 1.49 B | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.45 | -0.67 % | $ 652 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 1.04 | -6.31 % | $ 1.29 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.56 | -4.79 % | $ 4.05 B | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
-32.7 M | $ 5.27 | 0.96 % | $ 340 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.29 | -2.14 % | $ 309 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.47 | -2.65 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.23 | 2.49 % | $ 421 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.82 | 0.07 % | $ 17.8 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.41 | -0.55 % | $ 1.18 B | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.91 | -6.19 % | $ 3.92 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.04 | - | $ 116 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.24 | 2.99 % | $ 286 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.99 | -1.42 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.42 | -2.56 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.89 | 5.24 % | $ 32 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.56 | -4.13 % | $ 2.4 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.1 | 1.45 % | $ 24.3 M | USA |